Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 564-575, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soletormos, G.
Right arrow Articles by Dombernowsky, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soletormos, G.
Right arrow Articles by Dombernowsky, P.

Clinical Chemistry, Vol 42, 564-575, Copyright © 1996 by American Association for Clinical Chemistry

Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up

G Soletormos, D Nielsen, V Schioler, T Skovsgaard and P Dombernowsky
Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.

We investigated whether model systems integrating stochastic variation into criteria for marker assessment could be used for monitoring metastatic breast cancer. A total of 3989 serum samples was obtained from 204 patients receiving first-line chemotherapy and from 112 of these patients during follow-up. Each sample was analyzed for cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen. The efficiency for identifying progression and nonprogression was 94% during therapy and 85% during follow-up, with no false-positive marker results for progressive disease. At clinical progressive disease, the median positive lead time was 35 days during therapy and 76 days during follow-up. Tumor marker assessment may document that a therapy is effective and ought to be continued in spite of adverse toxic effects, and that a treatment is ineffective and should be stopped to prevent unnecessary toxicity. Marker information may also be useful in studies investigating whether early treatment during follow-up will alter the prognosis of metastatic breast cancer.


The following articles in journals at HighWire Press have cited this article:


Home page
 Postgrad. Med. J.Home page
S K Mohanty and P Dey
Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review
Postgrad. Med. J., October 1, 2003; 79(936): 569 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos, P. H. Petersen, and D. Nielsen
Computer-simulated Tumor-Marker Data Used to Compare Progression Criteria for Cytokeratin Tissue Polypeptide Antigen in Metastatic Breast Cancer
Clin. Chem., November 1, 2001; 47(11): 2035 - 2037.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos and V. Schioler
Description of a Computer Program to Assess Cancer Antigen 15.3, Carcinoembryonic Antigen, and Tissue Polypeptide Antigen Information during Monitoring of Metastatic Breast Cancer
Clin. Chem., August 1, 2000; 46(8): 1106 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos, P. Hyltoft Petersen, and P. Dombernowsky
Progression Criteria for Cancer Antigen 15.3 and Carcinoembryonic Antigen in Metastatic Breast Cancer Compared by Computer Simulation of Marker Data
Clin. Chem., July 1, 2000; 46(7): 939 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M.-H. Schlageter, J. Larghero, B. Cassinat, M.-E. Toubert, C. Borschneck, and J.-D. Rain
Serum Carcinoembryonic Antigen, Cancer Antigen 125, Cancer Antigen 15-3, Squamous Cell Carcinoma, and Tumor-associated Trypsin Inhibitor Concentrations during Healthy Pregnancy
Clin. Chem., September 1, 1998; 44(9): 1995 - 1998.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.